Key Performance
More- Earnings Score: 70
- Momentum Score: 32
- True Yield: N/A
- Financial Health Score: 55
%20scale(1,1)}%2025%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(1,1)}}%20%23ewMkZ6d8Hun3_ts%20{animation:%20ewMkZ6d8Hun3_ts__ts%204000ms%20linear%20infinite%20normal%20forwards}@keyframes%20ewMkZ6d8Hun3_ts__ts%20{%200%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}%2025%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}}%20]]%3e%3c/style%3e%3cdefs%3e%3clinearGradient%20id='ewMkZ6d8Hun2-fill'%20x1='12.5'%20y1='23.5001'%20x2='-0.868518'%20y2='16.4047'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun2-fill-0'%20offset='0%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun2-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3clinearGradient%20id='ewMkZ6d8Hun3-fill'%20x1='31.5059'%20y1='27.1026'%20x2='10.2884'%20y2='14.9373'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun3-fill-0'%20offset='4.7%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun3-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3c/defs%3e%3cg%20id='ewMkZ6d8Hun2_ts'%20transform='translate(24.943161,19.954806)%20scale(1,1)'%3e%3cpath%20d='M14.8466,29.2814c0,0-14.408088-4.6983-12.05895-19.79995c0,0,1.50345,4.85085,4.13448,5.30845s-2.03592,4.6373,7.92447,14.4915Z'%20transform='translate(-24.943161,-19.954806)'%20fill='url(%23ewMkZ6d8Hun2-fill)'/%3e%3c/g%3e%3cg%20id='ewMkZ6d8Hun3_ts'%20transform='translate(24.9787,20.012362)%20scale(1,1)'%3e%3cpath%20d='M37.4922,21.9282l4.0719.244v-12.81353C31.0713,3.28748,17.7595,7.6502,17.7595,7.6502c.3445-4.51526-3.5707-5.52204-3.5707-5.52204c2.5371,1.52542.3132,6.22373.3132,6.22373C13.0299,0.084092,0,1.02986,0,1.02986C8.92672,4.35528,6.70287,7.98579,6.8908,16.6197c.18794,8.6034,8.3943,12.9966,8.3943,12.9966l-6.60895-.2441v13.2407c0,0,5.48135,2.3797,13.68765,3.1729v-22.3017h-4.4477c-1.0023,0-1.942-.8237-1.942-1.8v-5.7356c0-.9763.9397-1.8,1.942-1.8h4.4477v-1.3424h5.0115v1.3424h5.0115c1.0023,0,1.848.7932,1.848,1.8v5.7356c0,.9763-.8144,1.8-1.848,1.8h-5.0115v22.5153h.2819c11.1192-.0611,15.9428-7.3221,16.256-13.3017.4698-7.7492-6.421-10.7695-6.421-10.7695Z'%20transform='translate(-24.9787,-20.012361)'%20fill='url(%23ewMkZ6d8Hun3-fill)'/%3e%3c/g%3e%3c/svg%3e)
Latest Research & News
Collegium Pharmaceutical Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Collegium Pharmaceutical announced the award of 50,305 restricted stock units (RSUs) to 34 newly hired non-executive employees on June 1, 2026, as material inducement for employment. The RSUs will vest over a three-year period with one-third vesting on June 10, 2027, followed by equal annual installments, subject to continued service.
06/05/2026, 8:00 AM • GlobeNewswire
Collegium to Participate in 2026 Jefferies Global Healthcare Conference
Collegium Pharmaceutical announced its management will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on June 3, 2026. The company, which specializes in CNS and pain management medications, recently completed the acquisition of AZSTARYS and reported Q1 2026 net revenues of $193.5 million, up 9% year-over-year, with JORNAY PM revenues up 36% year-over-year.
05/27/2026, 8:00 AM • GlobeNewswire
Collegium Completes Acquisition of AZSTARYS® from Corium Therapeutics
Collegium Pharmaceutical completed its acquisition of AZSTARYS, an ADHD treatment, from Corium Therapeutics for approximately $650 million. The acquisition is expected to be immediately accretive and includes patent protection through 2037. Collegium raised its 2026 financial guidance, projecting total product revenues of $865-$895 million and adjusted EBITDA of $475-$500 million, with expected annual synergies exceeding $50 million.
05/12/2026, 7:31 AM • Benzinga
Collegium's General Counsel Trims His Stake as the Company Doubles Down on ADHD
Collegium Pharmaceutical's General Counsel David Dieter sold 6,224 shares (6.4% of his holdings) for $228,110 under a pre-planned trading arrangement. The sale is modest and non-discretionary, but the real story is Collegium's strategic pivot toward ADHD treatments, with Jornay PM growing 48% in its first full year and the company acquiring AZSTARYS for $650 million to accelerate its move away from pain management.
03/30/2026, 9:12 PM • The Motley Fool
Collegium to Present New Real-World Data at PainConnect 2026
Collegium Pharmaceutical announced it will present two posters featuring real-world data from its pain medication portfolio at the American Academy of Pain Medicine's Annual Meeting in Salt Lake City (March 5-8, 2026). The presentations will highlight clinical insights on BELBUCA (buprenorphine buccal film) and its performance compared to other opioids, reflecting the company's focus on generating evidence for clinical practice.
03/05/2026, 8:00 AM • GlobeNewswire
Collegium Pharmaceutical announced a partnership with Paris Hilton to launch the 'Embrace Your Sparkle' campaign aimed at raising awareness about ADHD and reducing stigma. Paris Hilton shared her personal ADHD journey and her experience using JORNAY PM, an evening-dosed methylphenidate treatment designed to provide symptom support throughout the day. The campaign seeks to normalize conversations about ADHD management and encourage individuals to seek appropriate treatment.
03/03/2026, 8:00 AM • GlobeNewswire
Peers
Statistics
MoreInformation as of 06/22/2026
Company Profile
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily; Nucynta ER and Nucynta IR, which are extended-release and immediate-release oral formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. Collegium Pharmaceutical, Inc. was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. The company was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.